PGRN-CGM International Collaborative Studies

Core for Genomic Medicine

The U.S. NIH Pharmacogenomics Research Network (PGRN) is a consortium of research groups funded as individual cooperative agreements by the NIH. PGRN investigators are top researchers from U.S. academic institutions and conduct studies of variation in human genes relevant to drug metabolism, pharmacokinetics and pharmacodynamics, and the relationship of the genetic variation to drug responses. Principal investigators of the PGRN and RIKEN Center for Genomic Medicine (now RIKEN IMS Core for Genomic Medicine: CGM) held a series of discussions on the need to accelerate discoveries in pharmacogenomics (PGx) and launched the Global Alliance of Pharmacogenetics (GAP) in 2008. In this international collaboration, the PGRN has been successfully assembling an abundance of DNA samples from well-phenotyped patients receiving specific drugs and drug combinations in clinical trials conducted in the U.S. The CGM focuses on high-throughput genome-wide SNP scan with technological and methodological expertise to identify genetic factors associated with drug responses, risk of severe adverse drug reactions and non-response to medications. Together, the PGRN-CGM capitalizes on these strengths to advance discoveries in PGx research. More than 30 collaborative studies for various drug responses are ongoing to identify genomic biomarkers, which will develop better and safer medications and realize the dream of global personalized medicine.

Figure: Pharmacogenomics Research Network (PGRN) - RIKEN IMS Core for Genomic Medicine (CGM) strategic alliance


Back to Projects